Nasus Pharma reports faster epinephrine delivery in phase 2 study

March 16, 2026 7:30 AM

Nasus Pharma Ltd. (NYSE: NSRX) announced results from its Phase 2 clinical study of NS002, an intranasal epinephrine powder formulation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found